New therapies for the treatment of systemic lupus erythematosus

Bibliography

• JOHNSON AE, GORDON C, PALMER RG, BACON PA: The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum. (1995) 38(4):551-558.
   PubMed Web of Science ®Google Scholar
• SARZI-PUTTINI P, ATZENI F, IACCARINO L, DORIA A: Environment and systemic lupus erythematosus: an overview. Autoimmunity (2005) 38(7):465-472.
   PubMed Web of Science ®Google Scholar
• DEAFEN D, ESCALANTE A, WEINRIB L et al.: A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. (1992) 35(3):311-318.
   Google Scholar
• WAKELAND EK, LIU K, GRAHAM RR, BEHRENS TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity (2001) 15:397- 408.
   PubMed Web of Science ®Google Scholar
• ARBUCKLE MR, McCLAIN MT, RUBERTONE MV et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. (2003) 349(16):1526-1533.
   Google Scholar
• SUZUKI N, MIHARA S, SAKANE T: Development of pathogenic anti-DNA antibodies in patients with systemic lupus erythematosus. FASEB J. (1997) 11(12):1033-1038.
   PubMed Web of Science ®Google Scholar
• HAHN B: Mechanisms of disease: antibodies to DNA. N. Engl. J. Med. (1998) 338:1359-1368.
   Google Scholar
• DAVAS EM, TSIROGIANNI A, KAPPOU I et al.: Serum IL-6, TNFa, p55 srTNFa, p75 srTNFa, srIL-2a levels and disease acitivity in systemic lupus erythematosus. Clin. Rheumatol. (1999) 18(1):17-22.
   PubMed Web of Science ®Google Scholar
• LIU TF, JONES BM: Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine (1998) 10(2):140-147.
   PubMedGoogle Scholar
• HERRMANN M, VOLL RE, ZOLLER OM et al.: Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. (1998) 41(7):1241-1250.
   PubMed Web of Science ®Google Scholar
• MEVORACH D, ZHOU JL, SONG X, ELKON KB: Systemic exposure to irradiated apoptotic cells induces autoantibody production. J. Exp. Med. (1998) 188(2):387-392.
   Google Scholar
• THE CANADIAN HYDROXYCHLOROQUINE STUDY GROUP: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. (1991) 324(3):150-154.
   Google Scholar
• HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 6(8):2121-2131.
   Google Scholar
• CHAN T-M, LI F-K, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. (2000) 343:1156-1162.
   Google Scholar
• LIPSKY PE: Systemic lupus erythematosus: An autoimmune disease of B-cell hyperactivity. Nat. Immunol. (2001) 2(9):764-766.
   Google Scholar
• BOOTSMA H, SPRONK P, DERKSEN R et al.: Prevention of relapses in systemic lupus erythematosus. Lancet (1995) 345(8965):1595-1599.
   PubMedGoogle Scholar
• CVETKOVI SR, PERRY CM: Rituximab: a review of its use in non-hodgkins lymphoma and chronic lymphocytic leukaemia. Drugs (2006) 66:791-820.
   Google Scholar
• LEANDRO MJ, CAMBRIDGE G, EDWARDS JC, EHRENSTEIN MR, ISENBERG DA: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (2005) 44(12):1542-1545.
   PubMed Web of Science ®Google Scholar
• NG KP, LEANDRO MJ, EDWARDS JC et al.: Repeated B-cell depletion in treatment of refractory systemic lupus erythematosus. Ann. Rheum. Dis. (2006) 65(7):942-945.
   Google Scholar
• EISENBERG R, LOONEY RJ: The therapeutic potential of anti-CD20: what do B-cells do? Clinical Immunol. (2005) 117(3):207-213.
   PubMed Web of Science ®Google Scholar
• VIGNA-PEREZ M, HERNANDEZ-CASTRO B, PAREDES-SAHAROPULOS O et al.: Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Therapy (2006) 8(3):R83.
   Google Scholar
• LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B-cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580-2589.
   PubMed Web of Science ®Google Scholar
• TAHIR H, ROHRER J, BHATIA A, WEGENER WA, ISENBERG DA: Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (2005) 44(4):561-562.
   PubMed Web of Science ®Google Scholar
• TEDDER TF, TUSCANO J, SATO S, KEHRL JH: CD22, a B lymphocyte specific adhesion molecule that regulate antigen receptor signalling. Annu. Rev. Immunol. (1997) 15(1):481-504.
   Google Scholar
• LEONARD JP, COLEMAN M, KETAS JC et al.: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. (2004) 10(16):5327-5334.
   PubMed Web of Science ®Google Scholar
• DORNER T, KAUFMANN J, WEGENER W et al.: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Therapy (2006) 8(3):R74.
   Google Scholar
• MARSTERS SA, YAN M, PITTI RM et al.: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr. Biol. (2000) 10(13):785-788.
   Google Scholar
• YAN M, BRADY JR, CHAN B et al.: Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B-cell deficiency. Curr. Biol. (2001) 11(19):1547-1552.
   Google Scholar
• MACKAY F, SCHNEIDER P, RENNERT P, BROWNING J: BAFF and APRIL: a tutorial on B-cell survival. Annu. Rev. Immunol. (2003) 21:231-264.
   Google Scholar
• VARFOLOMEEV E, KISCHKEL F, MARTIN F et al.: APRIL-deficient mice have normal immune system development. Mol. Cell. Biol. (2004) 24(3):997-1006.
   Google Scholar
• ZHANG J, ROSCHKE V, BAKER KP et al.: Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. (2001) 166(1):6-10.
   PubMed Web of Science ®Google Scholar
• KOYAMA T, TSUKAMOTO H, MIYAGI Y et al.: Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann. Rheum. Dis. (2005) 64(7):1065-1067.
   PubMed Web of Science ®Google Scholar
• RAMANUJAM M, WANG X, HUANG W et al.: Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. (2004) 173(5):3524-3534.
   Google Scholar
• WALLACE D, LISSE J, STOHL W et al.: Belimumab (BmAb), a fully human monoclonal antibody to B lymphocyte stimulator (Blys), shows bioactivity and reduces systemic lupus erythematosus disease activity. Ann. Rheum. Dis. (2006) 65(Suppl. II):62.
   Google Scholar
• PETRI M, WALLACE D, STOHL W et al.: SLE patients with active production of anti-nuclear autoantibodies (ANA) have distinct patterns of lupus activity and peripheral B-Cell biomarkers compared to ANA negative. Ann. Rheum. Dis. (2006) 65(Suppl. II):356.
   Google Scholar
• VUGMEYSTER Y, SESHASAYEE D, CHANG W et al.: A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B-cells and lymphoid tissue marginal zone and follicular B-cells in cynomolgus monkeys. Am. J. Pathol. (2006) 168(2):476-489.
   PubMed Web of Science ®Google Scholar
• COUTTS SM, PLUNKETT ML, IVERSON GM, BARSTAD PA, BERNER CM: Pharmacological intervention in antibody mediated disease. Lupus (1996) 5(2):158-159.
   PubMed Web of Science ®Google Scholar
• FURIE RA, CASH JM, CRONIN ME et al.: Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. (2001) 28(2):257-265.
   Google Scholar
• ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 48(2):442-454.
   PubMed Web of Science ®Google Scholar
• LINNIK MD, HU JZ, HEILBRUNN KR et al.: Relationship between anti-double- stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. (2005) 52(4):1129-1137.
   PubMed Web of Science ®Google Scholar
• STRAND V, CRAWFORD B: Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Expert Rev. Pharmaco. Out. Res. (2005) 5(3):317-326.
   Google Scholar
• RAPOPORT MJ, SHARABI A, AHARONI D et al.: Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clinical Immunol. (2005) 117(3):262-270.
   Google Scholar
• ZINGER H, EILAT E, MESHORER A, MOZES E: Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB x NZW)F1 mice via active suppression. Int. Immunol. (2003) 15(2):205-214.
   Google Scholar
• STRAUSS SJ, MORSCHHAUSER F, RECH J et al.: Multicenter Phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-hodgkin's lymphoma. J. Clin. Oncol. (2006) 24(24):3880-3886.
   PubMed Web of Science ®Google Scholar
• ROSEN H, GOETZL EJ: Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. (2005) 5(7):560-570.
   Google Scholar
• OKAZAKI H, HIRATA D, KAMIMURA T et al.: Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J. Rheumatol. (2002) 29(4):707-716.
   Google Scholar
• TEDESCO-SILVA H, MOURAD G, KAHAN BD et al.: FTY720, a novel immunomodulator: Efficacy and safety results from the first Phase 2A study in de novo renal transplantation. Transplantation (2005) 79(11):1553-1560.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 355(11):1124-1140.
   PubMed Web of Science ®Google Scholar
• GINZLER EM, DOOLEY MA, ARANOW C et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. (2005) 353(21):2219-2228.
   Google Scholar
• CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. (2004) 350(10):971-980.
   Google Scholar
• HUGHES GRV, D'CRUZ DP: Mycophenolate mofetil: an advance in the therapy of autoimmune disease. Lupus (2005) 14(Suppl. 1):1-64.
   Google Scholar
• MOK CC, TONG KH, TO CH, SIU YP, AU TC: Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. (2005) 68:813-817.
   PubMed Web of Science ®Google Scholar
• TSE KC, LAM MF, TANG SC, TANG CS, CHAN TM: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus (2007) 16(1):46-61.
   PubMedGoogle Scholar
• FERNANDEZ D, BONILLA E, MIRZA N, NILAND B, PERL A: Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. (2006) 54:2983-2988.
   PubMed Web of Science ®Google Scholar
• EMERY P, KOSINSKI M, LI T et al.: Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J. Rheumatol. (2006) 33(4):681-689.
   Google Scholar
• DAIKH DI, WOFSY D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. (2001) 166(5):2913-2916.
   Google Scholar
• TAN PH, YATES JB, XUE S-A et al.: Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood (2005) 106(9):2936-2943.
   PubMed Web of Science ®Google Scholar
• MURPHY KM, NELSON CA, SEDY JR: Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. (2006) 6(9):671-681.
   Google Scholar
• GRAMMER AC, McFARLAND RD, HEANEY J, DARNELL BF, LIPSKY PE: Expression, regulation, and function of B-cell-expressed CD154 in germinal centers. J. Immunol. (1999) 163:4150-4159.
   PubMed Web of Science ®Google Scholar
• WANG X, HUANG W, SCHIFFER LE et al.: Effects of anti-CD154 treatment on B-cells in murine systemic lupus erythematosus. Arthritis Rheum. (2003) 48(2):495-506.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, FURIE R, MANZI S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. (2003) 48(3):719-727.
   PubMed Web of Science ®Google Scholar
• DAVIS JC Jr, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. (2001) 28(1):95-101.
   Google Scholar
• KALUNIAN KC, DAVIS JC Jr, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo- controlled trial. Arthritis Rheum. (2002) 46(12):3251-3258.
   PubMed Web of Science ®Google Scholar
• ARMANT M, FENTON M: Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol. (2002) 3(8):3011-3016.
   Google Scholar
• LEADBETTER EA, RIFKIN IR, HOHLBAUM AM et al.: Chromatin-IgG complexes activate B-cells by dual engagement of IgM and toll-like receptors. Nature (2002) 416(6881):603-607.
   PubMed Web of Science ®Google Scholar
• VALENCIA X, STEPHENS G, GOLDBACH-MANSKY R et al.: TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells. Blood (2006) 108(1):253-261.
   PubMed Web of Science ®Google Scholar
• TENBROCK K, JUANG Y-T, GOURLEY MF, NAMBIAR MP, TSOKOS GC: Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol. (2002) 169(8):4147-4152.
   PubMed Web of Science ®Google Scholar
• RAUOVA L, LUKAC J, LEVY Y, ROVENSKY J, SHOENFELD Y: High-dose intravenous immunoglobulins for lupus nephritis – a salvage immunomodulation. Lupus (2001) 10(3):209-213.
   PubMedGoogle Scholar
• JACOB CO, McDEVITT HO: TNF-α in murine autoimmune 'lupus' nephritis. Nature (1988) 331(6154):356-358.
   PubMed Web of Science ®Google Scholar
• GOMEZ D, CORREA PA, GOMEZ LM et al.: TH1/TH2 cytokines in patients with systemic lupus erythematosus: is TNF-α protective? Semin. Arthritis Rheum. (2004) 33(6):404-413.
   PubMed Web of Science ®Google Scholar
• DE BANDT M, SIBILIA J, LE LOET X et al.: Systemic lupus erythematosus induced by anti- TNF-α therapy: a French national survey. Arthritis Res. Therapy (2005) 7(3):R545-R551.
   Google Scholar
• SWALE VJ, PERRETT CM, DENTON CP, BLACK CM, RUSTIN MHA: Etanercept-induced systemic lupus erythematosus. Clin. Exp. Dermatol. (2003) 28(6):604-607.
   PubMed Web of Science ®Google Scholar
• ARINGER M, SMOLEN JS: TNF and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus (2004) 13(5):344-347.
   PubMed Web of Science ®Google Scholar
• SABRY A, SHEASHAA H, EL-HUSSEINI A et al.: Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine (2006) 35(3-4):148-153.
   PubMed Web of Science ®Google Scholar
• STUDNICKA-BENKE A, STEINER G, PETERA P, SMOLEN JS: TNF-α and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol. (1996) 35(11):1067-1074.
   PubMedGoogle Scholar
• SEGAL R, DAYAN M, ZINGER H, MOZES E: Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNF-α monoclonal antibody and by pentoxiphylline. Lupus (2001) 10(1):23-31.
   PubMed Web of Science ®Google Scholar
• ARINGER M, GRANINGER WB, STEINER G, SMOLEN JS: Safety and efficacy of TNF a blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum. (2004) 50(10):3161-3169.
   PubMed Web of Science ®Google Scholar
• PRUD'HOMME GJ, KONO DH, THEOFILOPOULOS AN: Quantitative polymerase chain reaction analysis reveals marked overexpression of IL-1β, IL-1 and IFN-γ mRNA in the lymph nodes of lupus-prone mice. Mol. Immunol. (1995) 32(7):495-503.
   Google Scholar
• BRENNAN DC, YUI MA, WUTHRICH RP, KELLEY VE: TNF and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury. J. Immunol. (1989) 143(11):3470-3475.
   PubMed Web of Science ®Google Scholar
• ALCOCER-VARELA J, ALEMAN-HOEY D, ALARCON-SEGOVIA D: IL-1 and -6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T cell activation markers. Lupus (1992) 1(2):111-117.
   PubMed Web of Science ®Google Scholar
• KIBERD BA, STADNYK AW: Established murine lupus nephritis does not respond to exogenous IL-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology (1995) 30(2):131-137.
   Google Scholar
• OSTENDORF B, IKING-KONERT C, KURZ K et al.: Preliminary results of safety and efficacy of the IL-1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis. (2005) 64(4):630-633.
   PubMed Web of Science ®Google Scholar
• SHARIF MN, TASSIULAS I, HU Y et al.: IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. (2004) 172(10):6476-6481.
   Google Scholar
• LLORENTE L, RICHAUD-PATIN Y: The role of IL-10 in systemic lupus erythematosus. J. Autoimmun. (2003) 20(4):287-289.
   Google Scholar
• LLORENTE L, RICHAUD-PATIN Y, COUDERC J et al.: Dysregulation of IL-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum. (1997) 40(8):1429-1435.
   PubMed Web of Science ®Google Scholar
• ISHIDA H, MUCHAMUEL T, SAKAGUCHI S et al.: Continuous administration of anti-IL-10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. (1994) 179(1):305-310.
   Google Scholar
• LLORENTE L, RICHAUD-PATIN Y, GARCIA-PADILLA C et al.: Clinical and biologic effects of anti-IL-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. (2000) 43(8):1790-1800.
   PubMed Web of Science ®Google Scholar
• KOUTOUZOV S, MATHIAN A, DALLOUL A: Type-I IFNs and systemic lupus erythematosus. Autoimmunity Rev. (2006) 5(8):554-562.
   Google Scholar
• SCHILLING PJ, KURZROCK R, KANTARJIAN H, GUTTERMAN JU, TALPAZ M: Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer (1991) 68(7):1536-1537.
   PubMed Web of Science ®Google Scholar
• WILSON LE, WIDMAN D, DIKMAN SH, GOREVIC PD: Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Sem. Arthritis Rheum. (2002) 32(3):163-173.
   Google Scholar
• MATHIAN A, WEINBERG A, GALLEGOS M, BANCHEREAU J, KOUTOUZOV S: IFN-α induces early lethal lupus in preautoimmune (New Zealand black x New Zealand white)F1 but not in BALB/c mice. J. Immunol. (2005) 174(5):2499-2506.
   PubMed Web of Science ®Google Scholar
• RYFFEL B, CAR BD, GUNN H et al.: IL-6 exacerbates glomerulonephritis in (NZBxNZW)F1 mice. Am. J. Pathol. (1994) 144(5):927-937.
   Google Scholar
• VAN VOLLENHOVEN RF, PARK JL, GENOVESE MC, WEST JP, MCGUIRE JL: A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus (1999) 8(3):181-187.
   PubMed Web of Science ®Google Scholar
• PETRI MA, LAHITA RG, VAN VOLLENHOVEN RF et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2002) 46(7):1820-1829.
   PubMed Web of Science ®Google Scholar
• CHANG DM, CHU SJ, CHEN HC, KUO SY, LAI JH: Dehydroepiandrosterone suppresses IL-10 synthesis in women with systemic lupus erythematosus. Ann. Rheum. Dis. (2004) 63(12):1623-1626.
   Google Scholar
• LINKER-ISRAELI M, ELSTNER E, KLINENBERG JR, WALLACE DJ, KOEFFLER HP: Vitamin D3 and Its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clinical Immunol. (2001) 99(1):82-93.
   Google Scholar
• LEMIRE J, INCE A, TAKASHIMA M: 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity (1992) 12(2):143-148.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ W, MOLD C, KATARANOVSKI M et al.: Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum. (2005) 52(2):642-650.
   PubMedGoogle Scholar
• LAI NS, LIN RH, LAI RS, KUN UC, LEU SC: Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice with an ancient Chinese herb, Ganoderma tsugae. Lupus (2001) 10(7):461-465.
   PubMed Web of Science ®Google Scholar